博雅生物(300294.SZ):華潤醫藥控股將成為公司控股股東
格隆匯 9 月 30日丨博雅生物(300294.SZ)公佈,鑑於公司的控股股東深圳市高特佳投資集團有限公司(“高特佳集團”)擬向華潤醫藥控股有限公司(“華潤醫藥控股”“收購人”)轉讓其持有的公司6933.1978萬股無限售流通股股份(佔發行前公司總股本的16.00%),擬將其於此次股份轉讓完成後所直接持有的博雅生物全部剩餘股份(不含高特佳集團通過其控股子公司深圳市融華投資有限公司持有的公司252.8334萬股股票)之表決權委託給華潤醫藥控股(表決權委託的股份數量為5704.964萬股,佔此次發行前公司總股本的比例為13.17%);
此外,公司擬向華潤醫藥控股發行股票,華潤醫藥控股擬全額認購公司向其發行的8666.4972萬股股份。
按照此次發行股份數量為8666.4972萬股計算,此次發行完成後,華潤醫藥控股通過受讓原有股份、表決權委託及認購向特定對象發行的股份,將持有公司155,996,950股股票,佔此次發行後公司總股本的30%,合計將擁有公司213,046,590股股票的表決權,佔此次發行後公司總股本的40.97%。
此次交易完成後,公司控股股東和實際控制人將發生變化,華潤醫藥控股將成為公司控股股東,中國華潤有限公司(“中國華潤”)將成為公司實際控制人,國務院國有資產監督管理委員會(“國務院國資委”)將成為公司最終實際控制人。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.